Mangalam Drugs And Organics Limited — Board Meeting, 07-08-2025: Outcome of Board Meeting

Mangalam Drugs & Organics' board approved consolidated financial results for Q1 FY26 (ended June 30, 2025). Sales stood at Rs 57.21 Cr, a notable decline from Rs 76.54 Cr last year and Rs 73.04 Cr last quarter. The company reported a Net Loss of Rs 13.80 Cr for the quarter, compared to a profit previously. Basic EPS was (8.72). The board also reviewed the ongoing merger plans with Mangalam Laboratories and Shri JB Pharma. An NCLT meeting for shareholders and creditors is set for August 12, 2025 regarding this scheme. #MDOL #Earnings